Dare Bioscience (DARE) Free Cash Flow (2013 - 2025)
Dare Bioscience's (DARE) quarterly Free Cash Flow came in at $1.1 million in Q4 2025, down 76.94% YoY from $4.8 million in Q4 2024, and up 314.16% on a QoQ basis from -$514857.0 in Q3 2025.
Dare Bioscience (DARE) Free Cash Flow (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Free Cash Flow data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Free Cash Flow fell 76.94% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.3 million (down 309.59% YoY) and the FY2025 annual result came in at -$10.3 million, down 309.59% from the prior year.
- Free Cash Flow advanced to $1.1 million in Q4 2025, from -$514857.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $12.9 million in Q2 2024 to a low of -$16.1 million in Q1 2023.
- A 5-year average of -$4.6 million and a median of -$6.3 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow surged 546.97% — and 2023, when it tumbled 194.16%.
- Tracing DARE's Free Cash Flow over 5 years: stood at -$9.9 million in 2021, then surged by 40.97% to -$5.8 million in 2022, then slumped by 39.85% to -$8.2 million in 2023, then jumped by 158.62% to $4.8 million in 2024, then tumbled by 76.94% to $1.1 million in 2025.
- The last three Free Cash Flow figures came in at $1.1 million (Q4 2025), -$514857.0 (Q3 2025), and -$5.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | -514,857.00 |
| Sep 30, 2025 | -514,857.00 |
| Jun 30, 2025 | -5.37 Mn |
| Jun 30, 2025 | -5.37 Mn |
| Mar 31, 2025 | -5.49 Mn |
| Mar 31, 2025 | -5.49 Mn |
| Dec 31, 2024 | 4.78 Mn |
| Dec 31, 2024 | 4.78 Mn |
| Sep 30, 2024 | -5.97 Mn |
| Sep 30, 2024 | -5.97 Mn |
| Jun 30, 2024 | 12.91 Mn |
| Jun 30, 2024 | 12.91 Mn |
| Mar 31, 2024 | -6.82 Mn |
| Mar 31, 2024 | -6.82 Mn |
| Dec 31, 2023 | -8.16 Mn |
| Dec 31, 2023 | -8.16 Mn |
| Sep 30, 2023 | -7.95 Mn |
| Sep 30, 2023 | -7.95 Mn |